← Leaderboards
Deepak Shukla
University Of Illinois At Chicago
$19,733,938
Attributed
$24,021,232
Total exposure
22
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,128,117 · 23
By mechanism
R01$14,629,601 · 7
P30$6,603,256 · 7
R24$4,325,995 · 1
R21$2,192,274 · 5
R56$581,037 · 1
K02$530,955 · 1
Top collaborators
- Abhijit A Date6 shared
- Afsar Raza Naqvi5 shared
- Vaibhav Tiwari2 shared
- Justin Richner1 shared
- Joel Schwartz1 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Abhijit A Date$4,064,660
- Mark I Rosenblatt$11,452,072
- Sandeep Jain$16,705,715
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionCellsViralBlindnessIn VivoSimplexvirusCorneaMouse ModelHerpesvirus 1VirusMolecularHerpetic KeratitisEye InfectionsProteinsPreventTissuesBaseHerpesviridae InfectionsVirus DiseasesAntiviral AgentsInflammationComplexPathway InteractionsReceptor
Grant awards (79)
Alleviation of ER stress as a translational strategy to curb ocular viral infections$1,089,050
R24 · FY2025 · EY · contact PI
Repurposing and reformulation of adefovir dipivoxil for improved topical treatment of herpes simplex virus infection of the eye$639,940
R01 · FY2025 · EY
P30 Core Grant for Vision Research$638,938
P30 · FY2025 · EY · contact PI
Autophagic Regulation of Eye Interaction$637,333
R01 · FY2025 · EY · contact PI
A new molecular therapy against ocular herpes$533,537
R01 · FY2025 · EY · contact PI
HPSE in Ocular Herpes Infection$422,753
R01 · FY2025 · EY · contact PI
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes$410,000
R01 · FY2025 · EY · contact PI
Imaging and Image Analysis Core$196,041
P30 · FY2025 · EY · contact PI
Administrative Core$53,125
P30 · FY2025 · EY · contact PI
Autophagic Regulation of Eye Interaction$50,000
R01 · FY2025 · EY · contact PI
Alleviation of ER stress as a translational strategy to curb ocular viral infections$1,094,442
R24 · FY2024 · EY · contact PI
Repurposing and reformulation of adefovir dipivoxil for improved topical treatment of herpes simplex virus infection of the eye$657,537
R01 · FY2024 · EY
P30 Core Grant for Vision Research$638,938
P30 · FY2024 · EY · contact PI
A new molecular therapy against ocular herpes$533,537
R01 · FY2024 · EY · contact PI
HPSE in Ocular Herpes Infection$422,753
R01 · FY2024 · EY · contact PI
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes$410,000
R01 · FY2024 · EY · contact PI
Imaging and Image Analysis Core$196,041
P30 · FY2024 · EY · contact PI
Administrative Core$53,125
P30 · FY2024 · EY · contact PI
Alleviation of ER stress as a translational strategy to curb ocular viral infections$1,061,330
R24 · FY2023 · EY · contact PI
P30 Core Grant for Vision Research$638,938
P30 · FY2023 · EY · contact PI
Mechanisms of Immune Dysfunction in Oral Post-Acute Sequelae of Covid-19$581,037
R56 · FY2023 · DE
A new molecular therapy against ocular herpes$476,059
R01 · FY2023 · EY · contact PI
HPSE in Ocular Herpes Infection$422,753
R01 · FY2023 · EY · contact PI
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes$410,000
R01 · FY2023 · EY · contact PI
Imaging and Image Analysis Core$196,041
P30 · FY2023 · EY · contact PI
Administrative Core$53,125
P30 · FY2023 · EY · contact PI
Alleviation of ER stress as a translational strategy to curb ocular viral infections$1,081,173
R24 · FY2022 · EY · contact PI
P30 Core Grant for Vision Research$638,938
P30 · FY2022 · EY · contact PI
A new molecular therapy against ocular herpes$462,153
R01 · FY2022 · EY · contact PI
HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes$410,000
R01 · FY2022 · EY · contact PI
HPSE in Ocular Herpes Infection$387,758
R01 · FY2022 · EY · contact PI
Imaging and Image Analysis Core$196,041
P30 · FY2022 · EY · contact PI
Administrative Core$53,125
P30 · FY2022 · EY · contact PI
P30 Core Grant for Vision Research$638,938
P30 · FY2021 · EY · contact PI
A new molecular therapy against ocular herpes$462,549
R01 · FY2021 · EY · contact PI
A small molecule inhibitor of HSV genital infections$399,750
R01 · FY2021 · AI · contact PI
HPSE in Ocular Herpes Infection$387,757
R01 · FY2021 · EY · contact PI
Imaging and Image Analysis Core$196,041
P30 · FY2021 · EY · contact PI
Administrative Core$53,125
P30 · FY2021 · EY · contact PI
P30 Core Grant for Vision Research$638,813
P30 · FY2020 · EY · contact PI
A new molecular therapy against ocular herpes$477,226
R01 · FY2020 · EY · contact PI
HPSE in Ocular Herpes Infection$399,750
R01 · FY2020 · EY · contact PI
A small molecule inhibitor of HSV genital infections$399,750
R01 · FY2020 · AI · contact PI
Imaging and Image Analysis Core$198,447
P30 · FY2020 · EY · contact PI
Administrative Core$52,094
P30 · FY2020 · EY · contact PI
P30 Core Grant for Vision Research$636,691
P30 · FY2019 · EY · contact PI
A new molecular therapy against ocular herpes$492,575
R01 · FY2019 · EY · contact PI
A small molecule inhibitor of HSV genital infections$399,750
R01 · FY2019 · AI · contact PI
HPSE in Ocular Herpes Infection$399,750
R01 · FY2019 · EY · contact PI
Innate and Adaptive Responses to HSV-2 Conjugated ZOTEN$199,875
R21 · FY2019 · AI · contact PI
P30 Core Grant for Vision Research$636,691
P30 · FY2018 · EY · contact PI
HPSE in Ocular Herpes Infection$399,750
R01 · FY2018 · EY · contact PI
A small molecule inhibitor of HSV genital infections$399,750
R01 · FY2018 · AI · contact PI
Innate and Adaptive Responses to HSV-2 Conjugated ZOTEN$239,850
R21 · FY2018 · AI · contact PI
Heparanase in Herpes Simplex Virus Pathogenesis and Disease$199,875
R21 · FY2018 · AI · contact PI
A new molecular therapy against ocular herpes$399,750
R01 · FY2017 · EY · contact PI
Heparanase in Herpes Simplex Virus Pathogenesis and Disease$239,850
R21 · FY2017 · AI · contact PI
A new molecular therapy against ocular herpes$399,750
R01 · FY2016 · EY · contact PI
A new molecular therapy against ocular herpes$47,090
R01 · FY2016 · EY · contact PI
A new molecular therapy against ocular herpes$399,521
R01 · FY2015 · EY · contact PI
Novel Peptides Against Modified Heparan Sulfate$193,011
R21 · FY2015 · AI · contact PI
Novel Peptides Against Modified Heparan Sulfate$246,550
R21 · FY2014 · AI · contact PI
Micro-nano Platforms for HSV Vaccine$199,375
R21 · FY2014 · AI · contact PI
Role of Optineurin in Ocular Herpes Infection$195,388
R21 · FY2014 · EY · contact PI
Micro-nano Platforms for HSV Vaccine$239,250
R21 · FY2013 · AI · contact PI
Role of Optineurin in Ocular Herpes Infection$239,250
R21 · FY2013 · EY · contact PI
Significance of heparan sulfate in HSV-1 spread$106,191
K02 · FY2013 · AI · contact PI
Significance of heparan sulfate in HSV-1 spread$106,191
K02 · FY2012 · AI · contact PI
Significance of heparan sulfate in HSV-1 spread$106,191
K02 · FY2011 · AI · contact PI
Significance of heparan sulfate in HSV-1 spread$106,191
K02 · FY2010 · AI · contact PI
Molecular Mechanism of HSV Entry and Spread$284,468
R01 · FY2009 · AI · contact PI
Significance of heparan sulfate in HSV-1 spread$106,191
K02 · FY2009 · AI · contact PI
Molecular Mechanism of HSV Entry and Spread$15,643
R01 · FY2009 · AI · contact PI
Molecular Mechanism of HSV Entry and Spread$284,468
R01 · FY2008 · AI · contact PI
Molecular Mechanism of HSV Entry and Spread$289,977
R01 · FY2007 · AI · contact PI
Molecular Mechanism of HSV Entry and Spread$298,638
R01 · FY2006 · AI · contact PI
Molecular Mechanism of HSV Entry and Spread$305,826
R01 · FY2005 · AI
Role of 3-0-sulfotransferases in HSV entry$107,488
K22 · FY2003 · AI
Role of 3-0-sulfotransferases in HSV entry$157,511
K22 · FY2002 · AI